Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Speedel focuses pipeline

Speedel (SWX:SPPN) said it will focus its pipeline on avosentan (SPP301) for diabetic nephropathy and its next-generation renin inhibitors and will

Read the full 217 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE